Evoke Pharma (EVOK) has released an update.
Evoke Pharma, Inc. has successfully closed its public offering, selling over 5 million common stock units and nearly 6 million pre-funded warrant units, with an additional issuance of warrants to the underwriters. This strategic financial move, buoyed by the anticipated revenue from their product GIMOTI, aims to secure the company’s operational funding for the upcoming year. Investors and market watchers should note, however, that while the company’s projections are positive, they are forward-looking statements subject to market risks and uncertainties.
For further insights into EVOK stock, check out TipRanks’ Stock Analysis page.
